c. difficile toxoid vaccine
Vaccineexperimental
Clinical trial activity
6 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
2
Phase 4
0
Earliest trial started Nov 1, 2005 (NCT00214461)
Timeline
Indications
Mechanism of action
- Clostridium difficileImmunity, active
Clostridium difficile immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- c. difficile toxoid vaccine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07282665 | Phase 3 | Dec 12, 2025 | Pfizer |
| NCT05805826 | Phase 2 | Mar 23, 2023 | Pfizer |
| NCT02052726 | Phase 1 | Jan 1, 2014 | Pfizer |
| NCT01887912 | Phase 3 | Jul 1, 2013 | Sanofi |
| NCT01706367 | Phase 1 | Sep 1, 2012 | Pfizer |
| NCT00214461 | Phase 1 | Nov 1, 2005 | Orlando Clinical Research Center, Sanofi, University of Kentucky |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 4 | 4 | 3 | 2012 |
| Sanofi | For profit | 2 | 2 | 2 | 2005 |
| Orlando Clinical Research Center | For profit | 1 | 0 | 1 | 2005 |
| University of Kentucky | Academic/Hospital | 1 | 0 | 1 | 2005 |
4 organizations
Page 1 / 1